NDEI.org

Premier destination for HCP diabetes education that addresses knowledge and practice gaps to enhance patient care

  • Home
  • Clinical Guidelines > Metabolic Surgery for the Treatment of Type 2 Diabetes – 2nd Diabetes Surgery Summit (DSS-II) in collaboration with international diabetes organization


  • Printer-Friendly Format
  • Email to a Colleague

Diabetes Management Guidelines

Metabolic Surgery for the Treatment of Type 2 Diabetes –
2nd Diabetes Surgery Summit (DSS-II) in collaboration with international diabetes organizations

Fonseca commentary 



Source: Rubino F, Nathan DM, Eckel RH, et al. Metabolic surgery in the treatment algorithm for type 2 diabetes: a joint statement by international diabetes organizations. Diabetes Care. 2016;39:861-877. Available here. 

Refer to source document for full recommendations, including class of recommendation and level of evidence.

Jump to a topic
Type 2 Diabetes Treatment Algorithm
Patient Selection
Preoperative Workup
Metabolic Surgery Types
Postoperative Follow-Up
Summary of Recommendations  

Algorithm for the Treatment of Type 2 Diabetes 
Type 2 Diabetes Treatment Algorithm These indications are intended for patients who are appropriate candidates for elective surgery.
Click slide to view larger.  
Metabolic Surgery for Type 2 Diabetes Type 2 Diabetes Treatment Algorithm   
 Back to top  
 
Patient Selection 
Contraindications for metabolic surgery: Grade A 
  • Type 1 diabetes diagnosis – unless surgery is otherwise indicated, such as for severe obesity
  • Current drug or alcohol abuse
  • Uncontrolled psychiatric illness
  • Lack of comprehension of the risks/benefits, expected outcomes, alternatives
  • Lack of commitment to nutritional supplementation, long-term follow-up
  • In adolescent patients, GI surgery is inappropriate (Grade U)  
 

Metabolic surgery is recommended as a treatment option in patients with:

  • Class III obesity (BMI ≥40 kg/m2)* regardless of the level of glycemic control or complexity of glucose-lowering regimens

Grade U  

  • Class II obesity (BMI 35.0-39.9)* with poor glycemic control despite lifestyle and optimal medical therapy

Grade A  

 

Metabolic surgery may be considered as a treatment option in patients with:

  • Class I obesity (BMI 30.0-34.9)* with poor glycemic control despite optimal medical treatment by oral or injectable medications

Grade B  

 
*BMI thresholds should be reconsidered depending on ancestry; reduce by 2.5 for Asian patients (Grade B)
Click slide to view larger.  
Metabolic Surgery for Type 2 Diabetes Patient Selection for Metabolic Surgery for the Treatment of Type 2 Diabetes   
 Back to top  
 
Preoperative Workup 
Patient evaluation
Grade U  
  • Include assessment of endocrine, metabolic, physical, nutritional, and psychological health
 
Evaluation
Grade A  
  • Include routine clinical tests and diabetes-specific metrics
  • Recommended tests:
    • Standard preoperative tests used for GI surgery at individual providers’ institution
    • Tests to characterize current diabetes status – eg, A1C, FPG, lipid panel
    • Tests to distinguish type 1 from type 2 – eg, fasting C-peptide, anti-GAD antibodies
     
 
Pre-surgery
Grade A  
  • Improve glycemic control!
  • Reduces risk for postoperative infection due to hyperglycemia
 
Click slide to view larger. 
Metabolic Surgery for Type 2 Diabetes Preoperative Workup for Metabolic Surgery for the Treatment of Type 2 Diabetes   
Back to top 
Metabolic Surgery Types 
RYGB (gastric bypass)
Grade U  
  • More favorable risk-benefit profile vs other options in most patients with type 2 diabetes  
 
Vertical sleeve gastrectomy (VSG)
Grade B  
  • Effective weight loss
  • Major improvement of type 2 diabetes in short to medium term (1-3 years – longer-term studies requried)
    • Valuable option for patients concerned about risk of operations with bowel diversion
     
 
Laparoscopic adjustable gastric banding (LAGB)
Grade B  
  • Effective in improving glycemia in patients with obesity and type 2 diabetes primarily by causing weight loss
    • Greater risk for reoperation/revision due to failure, complications
     
 
Biliopancreatic diversion (BPD)
Grade B  
  • Most complex surgery – most effective for glycemic control/weight loss but risk-benefit profile is less favorable
    • Significant risk of nutritional deficiencies
    • Highest perioperative morbidity/mortality
    • Should be considered only in patients with BMI >60  
     
 
Click slide to view larger. 
 Metabolic Surgery for Type 2 Diabetes Types of Metabolic Surgery Procedures for Treating Type 2 Diabetes   
 Back to top  

Postoperative Follow-Up 
After surgery, patients should be managed by multidisciplinary teams Grade A 
Evaluation
  • At least every 6 months during the first 2 postoperative years
  • At least annually thereafter
 
Monitor glycemic control as in standard care (Grade U) to avoid potential hyperglycemia relapse (Grade A)  
Stable nondiabetic glycemic for <5yrs
  • Monitor for complications
  • 5-yr remission: reduce monitoring frequency
  • Persistent normoglycemia & no complications: cease screening for complications

Grade B  

In first 6 months, evaluate for glycemic control and tapering of diabetes medications

  • After 6 months, further diabetes treatment should be dosed accordingly
  • Discontinue meds only after stable normoglycemia for at least two 3-month A1C cycles

Grade B  

If glucose levels quickly reach normoglycemic range early post-surgery:

  • Adjust therapy to prevent hypoglycemia
  • Metformin, TZDs, GLP-1 receptor agonists, DPP-4 inhibitors, alpha-glucosidase inhibitors, and SGLT2 inhibitors are suitable for early postoperative diabetes care

Grade A  

Offer ongoing and long-term monitoring of micronutrient status, nutritional supplementation, and patient support
 
Click slide to view larger.  
 Metabolic Surgery for Type 2 Diabetes Postoperative Follow-Up for Metabolic Surgery for Treating Type 2 Diabetes   
 Back to top  
 Summary of Recommendations 

Metabolic surgery is recommended to treat:

  • Type 2 diabetes in patients with Class II and Class III obesity when glycemia is inadequately controlled by lifestyle and optimal medical therapy
 

Metabolic surgery may be considered to treat:

  • Type 2 diabetes in patients with Class I obesity if glycemic control is poor despite optimal treatment with oral or injectable medications
 
Surgery should be performed in high-volume centers with multidisciplinary teams that understand and are experienced in the management of diabetes and GI surgery
Mortality rates with bariatric/metabolic operations are typically 0.1%-0.5%
Major complications rates are 2%-6%, with minor complications in up to 15
Postoperative follow-up: Ongoing and long-term monitoring of micronutrient status, nutritional supplementation, and support
Short/mid-term RCTs have shown that metabolic surgery achieves excellent glycemic control and reduces CV risk factors. Surgical value is more related to improved glucose homeostasis than weight loss. Additional studies are needed to demonstrate long-term benefits.
Click slide to view larger.  
 Metabolic Surgery for Type 2 Diabetes Summary of Recommendations for Treating Type 2 Diabetes With Metabolic Surgery   

Back to top  
 All slides available for download in the Slide Library. 


June 2016

This content was created by Ashfield Healthcare Communications, and was not associated with funding via an educational grant or a promotional/commercial interest.  

Back to
Clinical Guidelines 

BG Footer


Partner Site
CCMDweb.org


Sign Up
Please enter both email/username and
password to log in


Forgot Password?
  • Slide Library
  • Expert Commentary
  • Clinical Guidelines
  • Conference Coverage
  • Case Studies
  • Patient Education
  • Glossary
  • Product Indications
  • Professional Resources
  • Press Room
  • Calendar of Events
  • CME Opportunities





  • Facebook
  • Twitter
  • LinkedIn
  • YouTube

  • Home
  • About NDEI
  • Site Map
  • FAQ
  • Contact Us
  • Slide Library
  • Expert Commentary
  • Clinical Guidelines
  • Conference Coverage
  • Case Studies
  • Patient Education
  • Glossary
  • Product Indications
  • Professional Resources
  • Press Room
  • Calendar of Events
  • CME Opportunities

Sponsored by Ashfield Healthcare Communications, Lyndhurst, NJ. Copyright © 2016 Ashfield Healthcare Communications. All rights reserved.

  • Editorial Policy
  • Advertising Policy
  • Disclaimer Statement
  • Privacy Statement